New Delhi [India], The ninth edition of the Global Pharmaceutical Quality Summit took place here on Thursday, bringing together experts, industry leaders and stakeholders, among others, to foster knowledge sharing and deliberate on areas of importance in shaping the pharmaceutical landscape in India.
The Indian Pharmaceutical Alliance (IPA) today successfully concluded Day 1 of the 9th edition of the Global Pharmaceutical Quality Summit 2024.
The summit theme was “Advances in Manufacturing and Quality: Patient-Centered.”
The two-day Summit brings together industry leaders, global regulators, quality experts and stakeholders to foster knowledge sharing and deliberate on areas of importance in shaping the pharmaceutical landscape in India.
Dr. Arunish Chawla, Secretary, Department of Pharmaceuticals, delivered the keynote address and released the IPA Best Practice Guide on Good Engineering Practices and Process Analysis Tools.
During his speech, the Secretary said: "Quality is of utmost importance and is based on three essential pillars: market, patient and neighbor. Market quality demands a premium and builds reputation, which is our best defense against bad practices. “Patient quality is driven by strong regulatory systems, and India is making rapid progress on this front.”
He added: "Our mission going forward is to make quality the center of the policy framework. We have updated Annex M of the Drugs and Cosmetics Standards, surpassing WHO GMP standards in some areas."
"With audits starting in July 2024, we aim to produce world-class products, as emphasized by the Prime Minister's vision of 'Zero Defects and Zero Effect'. Quality requires investment and we support medium and small plants to through reform initiatives," he said.
"The integrity of the Indian industry depends on each player meeting the highest standards. When one fails, it affects the entire industry. Therefore, we must collectively champion quality to protect our reputation and ensure excellence in all aspects," he added.
The Indian Pharmaceutical Alliance (IPA) today successfully concluded Day 1 of the 9th edition of the Global Pharmaceutical Quality Summit 2024.
The summit theme was “Advances in Manufacturing and Quality: Patient-Centered.”
The two-day Summit brings together industry leaders, global regulators, quality experts and stakeholders to foster knowledge sharing and deliberate on areas of importance in shaping the pharmaceutical landscape in India.
Dr. Arunish Chawla, Secretary, Department of Pharmaceuticals, delivered the keynote address and released the IPA Best Practice Guide on Good Engineering Practices and Process Analysis Tools.
During his speech, the Secretary said: "Quality is of utmost importance and is based on three essential pillars: market, patient and neighbor. Market quality demands a premium and builds reputation, which is our best defense against bad practices. “Patient quality is driven by strong regulatory systems, and India is making rapid progress on this front.”
He added: "Our mission going forward is to make quality the center of the policy framework. We have updated Annex M of the Drugs and Cosmetics Standards, surpassing WHO GMP standards in some areas."
"With audits starting in July 2024, we aim to produce world-class products, as emphasized by the Prime Minister's vision of 'Zero Defects and Zero Effect'. Quality requires investment and we support medium and small plants to through reform initiatives," he said.
"The integrity of the Indian industry depends on each player meeting the highest standards. When one fails, it affects the entire industry. Therefore, we must collectively champion quality to protect our reputation and ensure excellence in all aspects," he added.
